Medarex, Ciba Form Partnership

July 1st 2025

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Gina Mauro

Serplulimab Earns UK Approval in Extensive-Stage Small Cell Lung Cancer

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Data from the phase 3 ASTRUM-005 trial support the MHRA’s approval of serplulimab for patients with extensive-stage small cell lung cancer.

Related Content

July 1st 2025

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Benjamin J. Golas, MD

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Gina Mauro

Serplulimab Earns UK Approval in Extensive-Stage Small Cell Lung Cancer

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.